Dabigatran

• Atrial Fibrillation Stroke Prevention
• Deep Vein Thrombosis (DVT)
• Pulmonary Embolism
• Blood Clot Prevention

Dabigatran etexilate is a direct thrombin inhibitor oral anticoagulant used for stroke prevention in atrial fibrillation, treatment and prevention of venous thromboembolism, and prevention of blood clots after hip replacement surgery. This medication was the first direct oral anticoagulant (DOAC) approved as an alternative to warfarin.

Mechanism of Action

Dabigatran etexilate is a prodrug that is converted to the active form dabigatran by esterases in the gut and liver. Dabigatran directly and reversibly inhibits thrombin (factor IIa), a serine protease that plays a central role in the coagulation cascade. Thrombin converts fibrinogen to fibrin, activates factors V, VIII, XI, and XIII, and activates platelets. By inhibiting thrombin, dabigatran prevents fibrin clot formation and reduces thrombin-mediated platelet activation. Unlike warfarin, dabigatran has rapid onset of action (within hours), predictable pharmacokinetics, and does not require routine laboratory monitoring.

Available Formulations

Dabigatran etexilate is available as oral capsules in 75 mg, 110 mg, and 150 mg strengths. The capsules must be swallowed whole and should not be opened, crushed, or chewed, as this significantly increases bioavailability and bleeding risk. The capsules should be stored in their original container and protected from moisture. Once opened, the container should be used within 4 months.

Medical Uses

Dabigatran is FDA-approved for reduction of stroke and systemic embolism risk in patients with non-valvular atrial fibrillation, treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients treated with a parenteral anticoagulant for 5-10 days, reduction of DVT and PE recurrence risk in patients previously treated, and prophylaxis of DVT and PE following hip replacement surgery. The RE-LY trial demonstrated non-inferiority to warfarin for stroke prevention with lower intracranial bleeding rates.

Dosing Guidelines

For atrial fibrillation with CrCl greater than 30 mL/min, the dose is 150 mg twice daily; for CrCl 15-30 mL/min, 75 mg twice daily is recommended. For DVT/PE treatment, 150 mg twice daily after 5-10 days of parenteral anticoagulation. For hip replacement prophylaxis, 110 mg on the first day followed by 220 mg once daily for 28-35 days. The medication should be taken at the same times each day. If a dose is missed, it should be taken as soon as possible unless it is within 6 hours of the next dose.

Important Safety Information

Dabigatran carries a boxed warning regarding premature discontinuation increasing stroke risk in atrial fibrillation patients and spinal/epidural hematoma risk with neuraxial anesthesia or spinal puncture. Major bleeding, including life-threatening and fatal bleeding, is the primary risk. Idarucizumab (Praxbind) is available as a specific reversal agent for emergencies. The medication should be discontinued 24-48 hours before invasive procedures depending on bleeding risk and renal function. Patients should avoid concomitant use with P-gp inducers.

Drug Interactions

P-glycoprotein (P-gp) inhibitors increase dabigatran levels. Avoid use with dronedarone or systemic ketoconazole. Reduce dose with concomitant P-gp inhibitors (verapamil, amiodarone, quinidine, clarithromycin) in patients with renal impairment. P-gp inducers (rifampin) significantly reduce levels and should be avoided. Concurrent use with antiplatelet agents, NSAIDs, or other anticoagulants increases bleeding risk. No food interactions occur, though food delays but does not reduce absorption.

Special Populations

Dabigatran should be avoided during pregnancy due to potential fetal harm (bleeding risk). It is unknown whether dabigatran is excreted in human breast milk; breastfeeding is not recommended. Safety and efficacy have not been established in pediatric patients. Elderly patients have increased drug exposure and bleeding risk; the 75 mg twice daily dose is recommended for those over 75 years in some countries. Dose reduction is required for renal impairment; the drug is contraindicated in severe impairment (CrCl less than 15 mL/min) and in patients on dialysis. No dose adjustment is needed for hepatic impairment.